Psychedelic Alpha provides clear, data-driven insights into the development, regulation, and commercialisation of psychedelic medicines, as well as broader policy and research developments across the field. We track the ecosystem globally, cut through the hype, and surface what matters with nuance to support informed decision-making by researchers, healthcare organisations, funders, and policymakers.

We publish in-depth analysis, interviews, bulletins, and maintain data resources including trackers, a legal map, and a drug development pipeline tracker. We also offer advisory and consultancy services, a curated job board, and a paid membership (Pα+) that provides subscribers and teams with exclusive briefings, archives, and tools.

To bring clarity, rigour, and context to the psychedelics field by delivering timely reporting, robust data, and expert analysis that helps stakeholders navigate research, regulation, and commercialisation.